Antibodies News and Research

RSS

Broadly neutralizing antibodies show promise in preventing tick-borne encephalitis in mice

Tick-borne encephalitis is a disease just as nasty as it sounds. Once bitten by an infected tick, some people develop flu-like symptoms that resolve quietly but leave behind rampant neurological disease--brain swelling, memory loss, and cognitive decline.

9 Apr 2021

Hay fever and asthma occur earlier in life and affect more people

The unpopular guests are already here. Hazel-, alder- and elm tree pollen sweep in over us during the early spring months, with birch pollen following in May. Then grass follows in June-July before mugwort pollen closes the season in late summer. All leading to more and more people suffering.

9 Apr 2021

Tiny SARS-CoV-2 protein may have big implications for future COVID-19 treatments

A tiny protein of SARS-CoV-2, the coronavirus that gives rise to COVID-19, may have big implications for future treatments, according to a team of Penn State researchers.

9 Apr 2021

Study points to the involvement of Interleukin 33 in immunity to Sars-CoV-2

Since the beginning of the coronavirus pandemic, scientists and physicians worldwide undertook enormous efforts to understand the disease caused by the virus.

9 Apr 2021

Frontline health workers experienced unprecedented levels of stress during the pandemic

During the acute phase of the COVID-19 pandemic, emergency department doctors, nurses and other frontline staff experienced unprecedented levels of stress and emotional exhaustion that included nightmares or insomnia, according to a UC San Francisco-led study of emergency departments across the country.

9 Apr 2021

Researchers discover a new monoclonal antibody that is effective against SARS-CoV-2 variants

A new monoclonal antibody targets a particular region of the RBD on the SARS-CoV-2. This region is usually not accessible to immune cells, which may be why it has broad neutralizing capabilities.

9 Apr 2021

Does natural infection with SARS-CoV-2 offer more protection than a vaccine against new variants?

A new study demonstrates that vaccines may be less effective at countering the newer SARS-CoV-2 variants compared to natural infection.

9 Apr 2021

Serum and breast milk SARS-CoV-2 antibodies correlated in vaccinated mothers

A new study shows the correlation between serum levels of antibodies to SARS-CoV-2 and levels in breast milk following the vaccination of lactating women with a vaccine based on mRNA technology.

9 Apr 2021

Oxford-AstraZeneca COVID vaccine induces cell spikes similar to SARS-CoV-2's

Scientists from the University of Oxford and the University of Southampton report in the journal ACS Central Science that cells infected with the ChAdOx1 vaccine produce spike proteins on the cells similar to those produced by natural SARS-CoV-2 infection.

9 Apr 2021

Powerful algorithms can 'predict' the biological language of cancer and Alzheimer's

Powerful algorithms used by Netflix, Amazon and Facebook can 'predict' the biological language of cancer and neurodegenerative diseases like Alzheimer's, scientists have found.

8 Apr 2021

Study finds more children infected by coronavirus during the second wave in Germany

A study by Helmholtz Zentrum München concludes that during the second Corona wave, three to four times more children in Bavaria, Germany were infected with the Corona virus than reported via PCR tests.

8 Apr 2021

Autoantibodies may contribute to severe COVID-19 and potential long-COVID-19 symptoms

New research in the USA and China. investigated how autoantibodies could mediate NETs during a COVID-19 infection. Extensive damage to the body from neutrophil extracellular traps (NETs) after infection may be contributing to thromboinflammation and the symptoms experienced by COVID-19 ‘long-haulers’.

8 Apr 2021

Moderna COVID-19 vaccine ensures long-term protection against SARS-CoV-2 infection, suggests study

A recent report published in the New England Journal of Medicine has revealed that the COVID-19 vaccine developed by Moderna, Inc, USA, is capable of inducing robust and durable antibody responses for at least six months post-vaccination.

8 Apr 2021

Prefusion SARS-CoV-2 spike-based vaccine candidate shows high safety and efficacy in phase I trial

A new preprint research paper posted to the medRxiv server reports the results of the first human trial of the prefusion stabilized SARS-CoV-2 spike vaccine MVC-COV1901 in Taiwan.

8 Apr 2021

Mouse monoclonal antibodies protect against SARS-CoV-2 wildtype, UK and South African variants

A new preprint research paper posted to the bioRxiv server reports on the ability of a set of neutralizing mouse antibodies to protect mice against multiple lineages of SARS-CoV-2.

8 Apr 2021

Study: 1 in 10 people still has moderate to severe symptoms after mild COVID-19

Eight months after mild COVID-19, one in ten people still has at least one moderate to severe symptom that is perceived as having a negative impact on their work, social or home life. The most common long-term symptoms are a loss of smell and taste and fatigue.

8 Apr 2021

Researchers identify mechanism by which dermatomyositis may develop in humans

Dermatomyositis is an idiopathic inflammatory myopathy that has been regarded as an autoimmunity-based disorder, although its pathogenesis remains unclear.

8 Apr 2021

Bispecific antibodies neutralize SARS-CoV-2 and its variants

A new bioRxiv preprint study led by Joshua Tan from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, involves generating bispecific antibodies using a new method cross-linking the antibodies with adjacent spike proteins using dual N-terminal domain/receptor binding domain specificity.

7 Apr 2021

Evidence of monoclonal antibodies effectively neutralizing SARS-CoV-2 variants

Makdasi et al. The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against novel viral variants. bioRxiv, 2021. doi: https://doi.org/10.1101/2021.04.01.438035, https://www.biorxiv.org/content/10.1101/2021.04.01.438035v2

7 Apr 2021

COVID-19 antibodies persist in breast milk for months following mother’s vaccination

Nursing mothers who receive a COVID-19 vaccine may pass protective antibodies to their babies through breast milk for at least 80 days following vaccination, suggests new research from Washington University School of Medicine in St. Louis.

7 Apr 2021

Antibodies News and Research

Broadly neutralizing antibodies show promise in preventing tick-borne encephalitis in mice

Hay fever and asthma occur earlier in life and affect more people

Tiny SARS-CoV-2 protein may have big implications for future COVID-19 treatments

Study points to the involvement of Interleukin 33 in immunity to Sars-CoV-2

Frontline health workers experienced unprecedented levels of stress during the pandemic

Researchers discover a new monoclonal antibody that is effective against SARS-CoV-2 variants

Does natural infection with SARS-CoV-2 offer more protection than a vaccine against new variants?

Serum and breast milk SARS-CoV-2 antibodies correlated in vaccinated mothers

Oxford-AstraZeneca COVID vaccine induces cell spikes similar to SARS-CoV-2's

Powerful algorithms can 'predict' the biological language of cancer and Alzheimer's

Study finds more children infected by coronavirus during the second wave in Germany

Autoantibodies may contribute to severe COVID-19 and potential long-COVID-19 symptoms

Moderna COVID-19 vaccine ensures long-term protection against SARS-CoV-2 infection, suggests study

Prefusion SARS-CoV-2 spike-based vaccine candidate shows high safety and efficacy in phase I trial

Mouse monoclonal antibodies protect against SARS-CoV-2 wildtype, UK and South African variants

Study: 1 in 10 people still has moderate to severe symptoms after mild COVID-19

Researchers identify mechanism by which dermatomyositis may develop in humans

Bispecific antibodies neutralize SARS-CoV-2 and its variants

Evidence of monoclonal antibodies effectively neutralizing SARS-CoV-2 variants

COVID-19 antibodies persist in breast milk for months following mother’s vaccination

How to make hybridoma-based antibody discovery more efficient eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo